{"id":5640,"date":"2026-08-20T13:40:40","date_gmt":"2026-08-20T13:40:40","guid":{"rendered":"https:\/\/crosscountrymovingteams.com\/?p=5640"},"modified":"2026-08-20T13:40:40","modified_gmt":"2026-08-20T13:40:40","slug":"game-changer-glp-1s-could-fix-americas-obesity-crisis-but-2-inequalities-stand-in-the-way","status":"publish","type":"post","link":"https:\/\/crosscountrymovingteams.com\/?p=5640","title":{"rendered":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way"},"content":{"rendered":"
\n

\u201cIt\u2019s a game-changer,\u201d Wenzel told Fortune<\/em>, describing how GLP-1s have shifted obesity treatment \u201cupstream\u201d\u2014from late-stage interventions like gastric bypass and orthopedic surgery toward proactive weight management that can head off disease before it starts. \u201cThat\u2019s what we\u2019re seeing, how this filters through the economics within healthcare.\u201d<\/p>\n

Read more You are paying for your favorite college athlete now: \u2018the next stage of the arms race\u2019<\/a><\/p>\n

The numbers back her up. A 2026 JAMA Surgery analysis found as GLP-1 use rose more than 140% between 2022 and 2024, bariatric surgery volumes fell 34.1% over the same stretch\u2014a direct substitution effect, according to a Wells Fargo Industry Insights report co-authored by Wenzel and John Teasley, a market executive in the bank\u2019s healthcare commercial banking group.<\/p>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n

Cardiovascular outcomes may be an even bigger story: The SELECT trial found semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes\u2014a result Wenzel called \u201can eye-opener\u201d given cardiology\u2019s status as one of the most lucrative lines of business within healthcare. Obesity therapies now account for roughly 25% of pharma\u2019s forecast late-stage drug pipeline value, up from just 1% in 2022, surpassing oncology for the first time in 16 years of tracking by Deloitte.<\/p>\n

Emerging research is also linking GLP-1s to reduced substance abuse, including alcohol use disorder. A Washington University School of Medicine study published in The BMJ in March found GLP-1 use was associated with an 18% lower risk of alcohol use disorder and similar reductions across other major addiction categories, adding to a growing body of clinical evidence the drugs\u2019 effects extend well beyond weight loss.<\/p>\n

A disease, not a failure of willpower<\/h2>\n

Central to Wenzel\u2019s framing is a reset of how obesity itself should be understood. <\/p>\n

\u201cIt\u2019s a very complex disease, a recognized medical disease,\u201d she said, pushing back on the historical medical framing that treated obesity primarily as a matter of \u201creshaping reasonable habits\u201d through diet and exercise. \u201cThe hope, and what we\u2019ve seen with GLP-1s, is it\u2019s finally giving people a path to truly address it and prevent it in many cases.\u201d<\/p>\n

\n
<\/div>\n<\/div>\n

That reframing has real economic backing. Federal health agencies now recognize obesity as a chronic disease shaped by genetics, environment, and food systems as much as individual behavior. A 2019 National Institutes of Health inpatient trial found people offered ultra-processed diets ate roughly 500 more calories per day than those given minimally processed meals\u2014even when the meals were matched for calories, sugar, fat, fiber and macronutrients. The federal government\u2019s 2025-2030 Dietary Guidelines for Americans, released Jan. 7, moved away from nutrient-counting advice and toward \u201creal food,\u201d a shift Wells Fargo\u2019s Agri-Food Institute says is already visible in how GLP-1 users shop.<\/p>\n

For all the clinical promise, Wenzel was candid about the industry\u2019s central unresolved problem: cost. <\/p>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n

\u201cWe all need to continue talking about the affordability of the drugs,\u201d she said. \u201cCoverage under different programs\u2014Medicare, Medicaid, or insurance\u2014doesn\u2019t always include access to GLP-1s for weight loss.\u201d<\/p>\n

\n
<\/div>\n<\/div>\n

List prices for Wegovy and Ozempic can be as high as $1,000 to $1,300 a month, according to Wenzel, and both major obesity drugs remain under patent, limiting competition. The Congressional Budget Office has estimated authorizing Medicare to cover anti-obesity medications broadly would add about $35 billion to federal spending between 2026 and 2034\u2014with near-term costs of roughly $5,600 per user in 2026 dwarfing the offsetting savings from improved health, estimated at just $50 per user that same year.<\/p>\n

\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n

\u201cThis is something that doesn\u2019t necessarily pencil out on an annual basis,\u201d Wenzel said. \u201cWe can see the weight loss, we can see the positive benefits,\u201d she added, but the way the drugs work is more like a process that plays out over time. <\/p>\n

Similar to her colleague at Wells Fargo, economist Michael Swanson, she compared the drugs directly to statins\u2019 role in cholesterol treatment: a chronic therapy that people may need to stay on for life, where meaningful results\u2014losing 20% of body weight, say\u2014unfold gradually rather than immediately. \u201cGLP-1s have a lot of similarities with statins\u2026 The benefit here is long-term.\u201d<\/p>\n

Read more Instagram took \u2018don\u2019t ask, don\u2019t tell\u2019 approach to kids, former engineer testifies \u2014\u00a0and pay was tied to keeping them online<\/a><\/p>\n

That framing points to a subtler problem than affordability alone: Even where GLP-1s are covered, the economics only work for patients\u2014and payers\u2014who can absorb years of cost before the benefit arrives. It is, in effect, a patience tax layered on top of a price tag\u2014and patience, like capital, is not evenly distributed. Two inequalities, of wealth and and of time, are the obstacle to the game-changing revolution in healthcare that these drugs represent. <\/p>\n

When asked if GLP-1s in general, and peptides in particular, are sort of like a healthcare equivalent to AI\u2019s potential as a general purpose technology, Wenzel said it was a fair comparison and we will have to wait and see how both play out.<\/p>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n

Relief is coming\u2014just not yet<\/h2>\n

Some price relief is already on the calendar. Novo Nordisk announced on Feb. 24 it will cut U.S. list prices for Wegovy by 50% and Ozempic by 35%, bringing both to $675 a month effective Jan. 1, 2027. Analysts cautioned, however, Novo plans to simultaneously reduce the rebates it pays to insurers and pharmacy benefit managers\u2014a move that could offset much of the list-price reduction in terms of actual net cost. <\/p>\n

Separately, the Centers for Medicare & Medicaid Services launched a temporary \u201cGLP-1 Bridge\u201d program on July 1, offering eligible Medicare beneficiaries access to the drugs for a $50 monthly copay through the end of 2027. State Medicaid programs have a parallel, voluntary pathway to adopt similar pricing under a model known as BALANCE.<\/p>\n

But both fixes are partial and temporary. The bridge program expires at the end of 2027 unless renewed. Coverage decisions remain fragmented at the state level: As of early 2026, only 13 states covered GLP-1s for obesity through Medicaid, while four states\u2014California, New Hampshire, Pennsylvania, and South Carolina\u2014eliminated that coverage entirely effective Jan. 1, regardless of manufacturer price cuts. Roughly 64% of large employers say covering GLP-1s for weight loss has meaningfully increased their prescription drug spending, according to the Peterson-KFF Health System Tracker, a pressure that is pushing some insurers to tighten prior-authorization requirements rather than loosen them.<\/p>\n

Patent timelines complicate the picture further. Wenzel pointed to patent expirations over the next several years as a path toward Medicare\u2019s ability to negotiate lower prices\u2014and international markets do move faster, with semaglutide\u2019s patent protection lapsing in China, India, and Canada as early as 2026.<\/p>\n

\n
<\/div>\n<\/div>\n

Meanwhile, competitive pressure between manufacturers is already reshaping pricing dynamics independent of patent expiration. Eli Lilly has overtaken Novo Nordisk in U.S. market share\u201460.9% to 38.8% as of August\u2014driven partly by its rival obesity drug, Zepbound, and an oral pill in development that Goldman Sachs projects could capture 60% of the daily-pill segment by 2030. Novo and Lilly together still control more than 90% of the premium GLP-1 market, meaning pricing so far reflects a two-company duopoly rather than genuine market competition.<\/p>\n

Asked whether this amounts to an inequality story, Wenzel didn\u2019t hesitate\u2014but she also expressed hope the current imbalance would narrow. <\/p>\n

\n
\n
<\/div>\n<\/div>\n<\/div>\n

\u201cThe hope is that the playing field evens out over time,\u201d she said. \u201cA wide percentage of population stands to benefit from these drugs. Right now it is tough, it\u2019s expensive, insurance doesn\u2019t necessarily cover it unless you meet certain criteria. Because of all of that, it\u2019s not widely available.\u201d<\/p>\n

For this story,\u00a0<\/em>Fortune\u00a0journalists used generative AI as a research tool. An editor verified the accuracy of the information before publishing.<\/em><\/p>\n

Read more Trump\u2019s Canada tariff threat produces a deal with no public terms<\/a><\/p>\n

\n
<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Wells Fargo Industry Insights’ Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn’t “pencil out” too often.<\/p>\n","protected":false},"author":1,"featured_media":5639,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[313],"tags":[],"class_list":["post-5640","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1s"],"yoast_head":"\n\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/crosscountrymovingteams.com\/?p=5640\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team\" \/>\n<meta property=\"og:description\" content=\"Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil out" too often.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/crosscountrymovingteams.com\/?p=5640\" \/>\n<meta property=\"og:site_name\" content=\"Cross Country Moving Team\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T13:40:40+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/#\\\/schema\\\/person\\\/1b8121bfb9a1c55d1fff3fca675fceaa\"},\"headline\":\"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way\",\"datePublished\":\"2026-08-20T13:40:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640\"},\"wordCount\":1298,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/f11229921977fc6bbcb3789e3743454f.webp\",\"articleSection\":[\"GLP-1s\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640\",\"url\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640\",\"name\":\"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/f11229921977fc6bbcb3789e3743454f.webp\",\"datePublished\":\"2026-08-20T13:40:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/#\\\/schema\\\/person\\\/1b8121bfb9a1c55d1fff3fca675fceaa\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#primaryimage\",\"url\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/f11229921977fc6bbcb3789e3743454f.webp\",\"contentUrl\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/f11229921977fc6bbcb3789e3743454f.webp\",\"width\":1200,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?p=5640#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/#website\",\"url\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/\",\"name\":\"Cross Country Moving Team\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/#\\\/schema\\\/person\\\/1b8121bfb9a1c55d1fff3fca675fceaa\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/crosscountrymovingteams.com\"],\"url\":\"https:\\\/\\\/crosscountrymovingteams.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/crosscountrymovingteams.com\/?p=5640","og_locale":"en_US","og_type":"article","og_title":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team","og_description":"Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't \"pencil out\" too often.","og_url":"https:\/\/crosscountrymovingteams.com\/?p=5640","og_site_name":"Cross Country Moving Team","article_published_time":"2026-08-20T13:40:40+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#article","isPartOf":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640"},"author":{"name":"admin","@id":"https:\/\/crosscountrymovingteams.com\/#\/schema\/person\/1b8121bfb9a1c55d1fff3fca675fceaa"},"headline":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way","datePublished":"2026-08-20T13:40:40+00:00","mainEntityOfPage":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640"},"wordCount":1298,"commentCount":0,"image":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#primaryimage"},"thumbnailUrl":"https:\/\/crosscountrymovingteams.com\/wp-content\/uploads\/2026\/08\/f11229921977fc6bbcb3789e3743454f.webp","articleSection":["GLP-1s"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/crosscountrymovingteams.com\/?p=5640#respond"]}]},{"@type":"WebPage","@id":"https:\/\/crosscountrymovingteams.com\/?p=5640","url":"https:\/\/crosscountrymovingteams.com\/?p=5640","name":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way - Cross Country Moving Team","isPartOf":{"@id":"https:\/\/crosscountrymovingteams.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#primaryimage"},"image":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#primaryimage"},"thumbnailUrl":"https:\/\/crosscountrymovingteams.com\/wp-content\/uploads\/2026\/08\/f11229921977fc6bbcb3789e3743454f.webp","datePublished":"2026-08-20T13:40:40+00:00","author":{"@id":"https:\/\/crosscountrymovingteams.com\/#\/schema\/person\/1b8121bfb9a1c55d1fff3fca675fceaa"},"breadcrumb":{"@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/crosscountrymovingteams.com\/?p=5640"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#primaryimage","url":"https:\/\/crosscountrymovingteams.com\/wp-content\/uploads\/2026\/08\/f11229921977fc6bbcb3789e3743454f.webp","contentUrl":"https:\/\/crosscountrymovingteams.com\/wp-content\/uploads\/2026\/08\/f11229921977fc6bbcb3789e3743454f.webp","width":1200,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/crosscountrymovingteams.com\/?p=5640#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/crosscountrymovingteams.com\/"},{"@type":"ListItem","position":2,"name":"\u2018Game-changer\u2019 GLP-1s could fix America\u2019s obesity crisis\u2014but 2 inequalities stand in the way"}]},{"@type":"WebSite","@id":"https:\/\/crosscountrymovingteams.com\/#website","url":"https:\/\/crosscountrymovingteams.com\/","name":"Cross Country Moving Team","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/crosscountrymovingteams.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/crosscountrymovingteams.com\/#\/schema\/person\/1b8121bfb9a1c55d1fff3fca675fceaa","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/crosscountrymovingteams.com"],"url":"https:\/\/crosscountrymovingteams.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/posts\/5640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5640"}],"version-history":[{"count":0,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/posts\/5640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=\/wp\/v2\/media\/5639"}],"wp:attachment":[{"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/crosscountrymovingteams.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}